Catch up on all the latest news and developments from Cyprotex, your ADME-Tox specialists!
Don't miss a thing by signing up to receive our newsletters straight to your inbox.
News from Cyprotex
NAMs Resource Hub
Enjoy our brand-new NAMs Resource Hub, bringing together our latest scientific insights on New Approach Methodologies in drug discovery and safety assessment. This central hub gives you unlimited access to our expertise in advancing animal-free, human-relevant science aligned with global regulatory initiatives.
From in-depth webinars, scientific blogs to peer-reviewed publications, scientific posters and more, the hub provides a comprehensive library for researchers and innovators exploring NAMs across drug discovery and development.
Enterotoxicity Assay
Over 60% of drugs are taken orally, yet gastrointestinal toxicity remain a leading cause of early clinical trial failures. Cyprotex’s Enterotoxicity Assay offers a human-relevant, non-animal model designed to better predict GI safety.
Using 3D EpiIntestinal™ tissues, the assay captures the true complexity of the human intestine with multiple cell types, over 22 metabolic enzymes and clinically relevant transporters. With endpoints including GI toxicity, barrier integrity, permeability, transport and inflammatory response, it offers both acute and long-term insights to support regulatory-aligned safety testing.
Curious to learn more?
PK Profile Prediction
How can you confidently select efficacious dose regimens early in drug discovery?
Cyprotex’s pharmacokinetic prediction service delivers rapid, machine learning–driven simulations of human plasma PK for oral and intravenous regimens.
Using in vitro ADME data with or without compound structures, our approach offers exceptional flexibility, scaling seamlessly from a single compound to hundreds. With turnaround times as fast as 1–5 working days and publication-ready reports, we make PK prediction simple, reliable and efficient – all without the need for software licences or specialist staff training.
Cell Painting
Cyprotex’s new Cell Painting Assay brings powerful phenotypic profiling into the earliest stages of drug discovery. Flexible protocols and high-quality PoD endpoints provide rapid, detailed insights into compound effects. With a simple, automated workflow and multiplexed staining, our Cell Painting Assay enables deep exploration of cellular morphology.
This scalable, cost-effective approach uncovers mechanisms of action, predicts compound toxicity, and identifies phenotypic changes, helping you reduce risk and accelerate development with robust, high-quality insights.
Webinar: Integrating Mitochondrial Toxicity Screening Into Early Drug Discovery
Catch up on our latest short webinar in partnership with Technology Networks, part of the Teach Me in 10 minutes series, featuring Julie Eakins, Principal Scientist at Cyprotex.
You will learn how early mitochondrial toxicity screening improves drug safety and discover key in vitro assays and methods to reduce organ toxicity risks in drug development.
Register now to watch on demand.
Latest News from Parent Company, Evotec
READ THE PRESS RELEASES
Read more from Evotec, Cyprotex and Just - Evotec Biologics in our scientific resource hub - Science Pool:
Explore the Cyprotex e-Store
Easily access our ADME-Tox services anytime, anywhere:
- Order your ADME-Tox services online
- Instant pricing, protocols and ordering
- Range of payment options including secure credit card, invoice or purchase order
